Tonix Pharma (TNXP) has provided an update.
Tonix Pharmaceuticals has completed the clinical stage of its Phase 1 trial for TNX-1500, a potential new treatment, with results expected in the third quarter of 2024. While this marks a significant milestone, the company cautions investors about forward-looking statements, emphasizing that future performance is subject to various risks and uncertainties. This announcement underscores the company’s ongoing efforts in product development and highlights the anticipation for the trial’s outcomes, which could impact the company’s competitive position in the market.
Find detailed analytics on TNXP stock on TipRanks’ Stock Analysis page.
